Quick Answer
NRX Pharmaceuticals, Inc. reported R&D Expense of $3.78 million for fiscal year 2025.
NRX Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.78M | -39.1% |
| 2024 | $6.20M | -53.6% |
| 2023 | $13.37M | -21.5% |
| 2022 | $17.03M | -15.9% |
| 2021 | $20.26M | +90.7% |
| 2020 | $10.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.43M | +133.9% | +44.8% |
| June 30, 2025 | $987.0K | -64.8% | +61.5% |
| September 30, 2024 | $611.0K | -81.6% | -78.2% |
| June 30, 2024 | $2.80M | -27.6% | +60.4% |
| March 31, 2024 | $1.75M | +117.4% | -47.3% |
| September 30, 2023 | $3.31M | -19.7% | -14.4% |
| June 30, 2023 | $3.87M | +30.9% | +381.7% |
| March 31, 2023 | $804.0K | -85.3% | -80.5% |
- NRX Pharmaceuticals, Inc. showed a decrease of -39.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, NRX Pharmaceuticals, Inc.’s r&d expense has declined by 64.5% (from $10.62 million to $3.78 million).
- The most recent figure is from NRX Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: